top of page

Read Lab

High grade gliomas (HGGs), the most common primary brain tumors, are caused by mutations that perturb developmental and homeostatic processes in stem/progenitor cells in the central nervous system (CNS). Our goal is to determine how aspects of HGG cell biology and genetics can be effectively targeted to actively eliminate these tumor cells in the brain. To this end, our research addresses several outstanding questions in the field. For example, how do mutations in developmental signaling pathways promote malignancy? How do other pathways contribute to HGG initiation and progression? Which neural cell types undergo neoplastic transformation and why? How do cell-cell interactions in the neural microenvironment promote tumorigenesis? Can the molecular pathways driving HGG be effectively pharmacologically targeted for therapeutic benefit?

download.jpg

Glioblastoma

GBM39  DMSO 18 hr AO-EB 40x 1 redo A slc
Slide I Wide Angle A copy.tiff

Research Program

Our research program uses a multi-disciplinary approach to analyze the function of developmental cell-signaling pathways in tumorigenesis, spanning several types of brain tumor model systems, including mouse models of HGG, primary patient-derived human HGG stem cells, human iPS cell-derived brain organoid ('mini-brain') models, and Drosophila melanogaster HGG models. Current projects focus on the functional role of mutant variants of receptor tyrosine kinases (RTKs) and their downstream effectors in tumor initiation and progression, including the YAP and TAZ transcription factors. Our work also involves new clinical trials that target effectors of RTK signaling in HGG. Additional ongoing projects in our lab explore the role of cell-cell interactions and cell fate in the tumor microenvironment.

Our research program is aided by fun and productive collaborations with other neuro-oncology researchers in the Departments of Neurosurgery, Pediatrics, Human Genetics, Pathology, and Hematology and Medical Oncology, including clinical neurosurgical and neuropathology faculty. We welcome young scientists who seek to enter this dynamic field. Our trainees will have opportunities to work with our brain tumor model systems, perform drug testing experiments in pre-clinical paradigms, interface with clinical neuro-oncology faculty, and/or advocate for patient outreach and education.

We are located in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine in Atlanta, Georgia. Dr. Read is a member of the Neuroscience and Molecular Systems Pharmacology Graduate Programs and participates in the Cancer Biology program.

Our lab welcomes new and current members from all orientations, backgrounds, and nationalities to bring their passion and life experience to our work together to advance the discovery and development of new therapies and therapeutic targets for adult and pediatric brain tumors.   We also welcome trainees seeking research experiences on brain tumor therapeutic discovery and treatment at the interface of public health and community outreach.


Contact:  renee.read@emory.edu,  404-727-5985,  1510 Clifton Rd, Atlanta, GA 30322

bottom of page